When to Check Apolipoprotein B (Apo B)
Measure apo B when triglycerides are ≥200 mg/dL, when cardiovascular risk assessment is uncertain in intermediate-risk patients, or when hypertriglyceridemia is present to determine if it represents an atherogenic condition. 1
Primary Indications for Apo B Measurement
Hypertriglyceridemia
- Check apo B when triglycerides are ≥200 mg/dL to assess the true atherogenic particle burden, as LDL-C calculation becomes unreliable in this setting 1
- Apo B measurement is particularly useful in determining whether hypertriglyceridemia represents an atherogenic condition 1
- This is critical because each VLDL, IDL, and LDL particle contains one apo B molecule, making apo B a direct measure of total atherogenic particle number 2
Risk Assessment in Intermediate-Risk Patients
- Measure apo B as a risk-enhancing factor when cardiovascular risk is uncertain in adults aged 40-75 years undergoing primary prevention assessment 1
- An apo B level ≥130 mg/dL corresponds to an LDL-C ≥160 mg/dL and constitutes a risk-enhancing factor that favors initiation or intensification of statin therapy 1
- Persistently elevated apo B (ideally measured on 3 separate occasions) should be considered a risk-enhancing factor 1
High-Risk Metabolic Conditions
- Check apo B in patients with diabetes mellitus, metabolic syndrome, obesity, or insulin resistance, as these conditions are associated with discordance between LDL-C and apo B 2, 3
- In these populations, apo B more accurately reflects cardiovascular risk than LDL-C because of the presence of small, dense LDL particles and increased VLDL remnants 2, 3
Secondary Indications
Very Low LDL-C Levels
- **Measure apo B when LDL-C is <70 mg/dL (<1.8 mmol/L)**, particularly if triglycerides are >150 mg/dL, as the Friedewald calculation becomes unreliable at these levels 1, 4
- This is increasingly relevant in patients on intensive lipid-lowering therapy where accurate assessment of residual risk is needed 4, 3
Family History and Genetic Lipid Disorders
- Consider apo B measurement in adults with family history of premature ASCVD (males <55 years, females <65 years) to aid in identification of familial lipid disorders 1
- Apo B testing can inform family cascade screening when an inherited lipoprotein syndrome is identified 3
Monitoring Treatment Response
- Use apo B to assess residual cardiovascular risk in patients on lipid-lowering therapy, as it has been shown to be superior to LDL-C in risk assessment both before and during treatment 3, 5
- Apo B provides better risk stratification than LDL particle number when these markers are discordant 6
Clinical Context and Interpretation
Risk Thresholds
- Apo B ≥130 mg/dL is the threshold that constitutes a risk-enhancing factor and corresponds to LDL-C ≥160 mg/dL 1
- In young adults (18 to <40 years), maintaining usual apo B exposure <75 mg/dL may represent a goal to maintain low long-term ASCVD risk 7
Discordance Analysis
- When apo B is elevated despite normal or borderline LDL-C or non-HDL-C, the cardiovascular risk generally aligns better with the apo B level 3, 5
- Even modest discordance (as little as 2% between apo B and LDL particle number) may be clinically relevant and associated with increased cardiovascular events 6
- Elevated apo B independently predicts increased 20-year ASCVD risk, particularly when LDL-C is also elevated 5
Important Caveats
Laboratory Considerations
- Apo B measurement carries extra expense, and measurement reliability may vary between laboratories 1
- Despite these limitations, apo B is a validated clinical measurement with established standardization 8, 3